/C O R R E C T I O N -- Simcere Pharmaceutical Group/

In the news release, ''Simcere Pharmaceutical Group Announces Interim
Results of Endu Phase IV Clinical Study'', issued on Sept. 3 by Simcere
Pharmaceutical Group (NYSE: SCR) over PR Newswire, we are advised by the
company that under "Highlights of the interim results of Endu Phase IV
clinical study:", a term in the third point should read "CBR" instead of
"CBP", as originally issued inadvertently. The third point should read "The
overall response rate and clinical benefit rate were 24.13% and 81.22%
respectively. The response rates of the newly treated and previously treated
groups were 30.88% and 17.34%(P<0.05), corresponding to CBR 86.03% and
76.38%(P<0.05) respectively." Full, correct release follows. Simcere
Pharmaceutical Group Announces Interim Results of Endu Phase IV
Clinical Study
NANJING, China, Sept. 3 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical
Group (NYSE: SCR), a leading manufacturer and supplier of branded generic
pharmaceuticals and manufacturer of the patented anti-cancer biotech product
Endu (also known as Endostar) in China, announced the interim results of Endu
Phase IV clinical study.
At the request of the SFDA, Simcere initiated a Phase IV clinical study to
further validate the safety and therapeutic efficacy of Endu, a modified
version of recombinant human endostatin, in combination with platinum-based
chemotherapy, on large samples of patients in advanced stages of non-small
cell lung cancer (NSCLC). The primary endpoint of this study was to evaluate
the safety and therapeutic efficacy of Endu in conjunction with platinum-based
chemotherapy. It is designed as an open label, prospective, and multi-center
Phase IV study, which for the interim results, included 648 patients at the
advanced stages of NSCLC. This study is led by the center of Good Clinical
Practice (GCP) of Cancer Hospital of Chinese Academy of Medical Sciences.
Highlights of the interim results of Endu Phase IV clinical study:

-- Endu plus platinum-based chemotherapy produces synergistic activity
against advanced NSCLC;
-- The Endu-platinum chemotherapy regime was well tolerated, and
therapeutic efficacy was in accordance with that of the Phase III
study;
-- The overall response rate and clinical benefit rate were 24.13% and
81.22% respectively. The response rates of the newly treated and
previously treated groups were 30.88% and 17.34%(P<0.05),
corresponding to CBR 86.03% and 76.38%(P<0.05) respectively.

Professor Sun Yan, Member of Chinese Academy of Engineering, said: "The
interim results of the open-label, large sample, multi-center Endu phase IV
clinical study affirms the safety and therapeutic efficacy of Endu acting in
conjunction with platinum-based chemotherapy. With our continued research of
Endu Phase IV, we will collect more clinical data to further evaluate the
safety and efficacy of Endu."
To date, over 2,000 NSCLC patients have been recruited for Endu Phase IV
clinical study. The final results of the study will be announced in the first
half of 2010.
As a leading patented anti-cancer biotech product in China, Endu is
recommended in the National Comprehensive Cancer Network of China Clinical
Practice Guidelines in Oncology Chinese Version (2006-2008)as a first line
treatment for NSCLC.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading
manufacturer and supplier of branded generic pharmaceuticals and manufacturer
of the patented anti-cancer biotech product Endu in the rapidly growing China
market. In recent years, Simcere has been focusing its strategy on the
development of first-to-market generic and innovative pharmaceuticals, and has
introduced a first-to-market generic stroke management medication under the
brand name Bicun and an innovative anti-cancer medication under the brand name
Endu. Simcere currently manufactures and sells more than 50 pharmaceutical
products including antibiotics, anti-cancer medication and stroke management
medication and is the exclusive distributor of three additional
pharmaceuticals that are marketed under its brand names. Simcere concentrates
its research and development efforts on the treatment of diseases with high
incidence and/or mortality rates and for which there is a clear demand for
more effective pharmacotherapy such as cancer, strokes, osteoporosis and
infectious diseases and currently has more than 12 pipeline products. For more
information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contact:
Email: ir@simcere.com

In Nanjing:
Frank Zhao
Chief Financial Officer
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8818
E-mail: zhaozhigang@simcere.com

In the United States:
Michael Guerin
Brunswick Group LLC
Tel: 1-212-333-3810
E-mail: mguerin@brunswickgroup.com

In Beijing:
Kejia Wu
Brunswick Group
Tel: 86-10-6566-2256
Email: kwu@brunswickgroup.com

In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000
Email: clo@brunswickgroup.com

SOURCE Simcere Pharmaceutical Group

Investor and Media Contact, ir@simcere.com; In Nanjing: Frank Zhao, Chief
Financial Officer, Simcere Pharmaceutical Group, 86-25-8556-6666 ext 8818,
zhaozhigang@simcere.com, In the United States: Michael Guerin, Brunswick Group
LLC, +1-212-333-3810, mguerin@brunswickgroup.com, In Beijing: Kejia Wu,
Brunswick Group, 86-10-6566-2256, kwu@brunswickgroup.com, In Hong Kong: Joseph
Lo Chi-Lun, Brunswick Group, +1-852-3512-5000, clo@brunswickgroup.com